ARDELYX Q3 2026 EARNINGS - ARDELYX INC

Explicit Guidance:

• Ibsrela Revenue: Reaffirmed full-year 2026 guidance of $350 million to $370 million, representing annual growth of more than 30%.
• Exposra Revenue: Reaffirmed full-year 2026 revenue guidance of $110 million to $120 million.
• Operating Expenses: Full-year 2026 operating expenses expected to remain below $500 million.
• Profitability Timeline: Continued path to profitability anticipated in 2027, driven by revenue growth and disciplined expense management.
• Gross-to-Net (Current): Blended gross-to-net rate for Q3 2026 was 31.7% (vs. 30.6% in Q3 2025), with expectations for low-to-mid 30% going forward.

Business-Segment Outlook:

• Ibsrela (IBSC & CIC): Expectation to achieve $1 billion in annual revenue long-term. Growth driven by high HCP confidence, increasing total writers/prescriptions, and market share gains.
• CIC Expansion (Excel Trial): Fully enrolled the Phase 3 trial (CIC) ahead of schedule; top-line results expected in the second half of 2027. Anticipated to expand the addressable market significantly beyond the current IBSC indication.
• Ibsrela Access Strategies: Continued focus on eliminating payer friction via digital/AI tools, expanded Direct-to-Consumer (DTC) advertising (targeting >10 million people via streaming platforms), and doubling the Field Reimbursement Management (FRM) team to navigate prior authorization.
• Ibsrela Pharmacy Network (IPN): Transitioning patients to the IPN network expected to yield 2–3x higher fulfillment rates, faster fill times, and at least one additional refill per patient annually.
• Exposra (CKD): Demand remains high in the dialysis market with 70% of patients struggling to maintain target phosphorus levels; revenue growth driven by paid prescriptions (up 22% YoY) despite complex reimbursement environment.
• Pipeline: Financial position supports operations via internal cash flow, with no reliance on external financing for the near term.

Market and Competitive Outlook:

• IBSC/CIC Market: Over 7 million IVFC/IBSC prescriptions written annually; >70% of patients experience persistent symptoms. CIC market is significantly larger than IBSC, with significant patient volume currently treated with OTC products.
• Clinical Positioning: Real-world data suggests Ibsrela reduces GI-related healthcare resource utilization (fewer visits/labs) for both IBSC and potentially CIC patients.
• DTC Impact: Early indicators from September DTC campaign show meaningful impressions and increased traffic to consumer websites; 91% of tested patients indicated they would ask their physician about the drug.
• Prescribing Dynamics: Strong physician conviction in product efficacy; focus remains on converting interest to prescriptions by navigating bottom-of-funnel payer barriers.

Macro / Industry Outlook:

• Reimbursement Environment: Dialysis reimbursement described as "complex"; company taking a "thoughtful and measured approach" to ensure Exposra remains a positive contributor. No expectation of immediate resolution to payer friction challenges.
• Gross-to-Net Erosion: Anticipated continued slight erosion in gross-to-net rates due to business mix shifts, inflation rebates, and penalties.
• Contracting Strategy: Approach to contracting and rebating for 2027 and beyond will be "meaningfully slowly and thoughtfully," ensuring trade-offs yield patient benefits; no specific 2027 targets provided.
• Regulatory Path: Phase 3 trial enrollment ahead of schedule indicates strong enthusiasm from treating physicians; FDA feedback anticipated post-trial results in H2 2027.

Strategic Initiatives:

• Sales Force Expansion: Expanded sales force mid-year to increase reach/frequency; continued investment in FRM team to support prior authorization processes.
• DTC Launch: Launched first direct-to-consumer ad campaign in September targeting IBS/C patients via major streaming platforms (Netflix, Hulu, Prime Video, Disney+).
• Digital & AI Tools: Continuing assessment and deployment of digital and AI tools to streamline prior authorization and reduce friction.
• Capital Allocation: Maintaining "prudent expense management" and a "disciplined capital allocation strategy" to support pipeline growth and path to profitability.
• Liquidity: Retaining $285.3 million in cash and equivalents to fund operations and pipeline without external financing.

Risks and Headwinds to Outlook:

• Payer Friction: Ongoing difficulty in prior authorization and reimbursement could hinder adoption rates; management notes this is an industry-wide challenge requiring continuous tactical adjustment.
• Channel Mix & Inventory: Sequential fluctuations in revenue due to buying patterns and inventory levels at wholesalers (e.g., quarterly declines of ~9% noted for Exposra due to buying dynamics).
• Data Accuracy: Potential discrepancies in script reporting depending on data sources (e.g., projected vs. 100% capture with IPN); trends are monitored to confirm fundamentals.
• Trial Uncertainty: Clinical success of the CIC trial is not guaranteed; while confidence is high based on IBSC data, actual results and timing could vary.
• Long-term Financial Targets: No specific guidance provided for 2027 revenue or gross-to-net rates; management emphasizes patience until the current period ends and confidence is established.

Management Tone on the Future:

• Confidence Level: High confidence in the "strong foundation" and execution capability, citing the narrowed net loss ($700k) and robust cash position.
• Commitment: Strong commitment to "staying focused on execution" and "thoughtful" management of access initiatives.
• Forward-Looking Caution: Management avoids specific long-term numbers for 2027 and future gross-to-net metrics, emphasizing a "step-by-step" approach to reducing friction rather than expecting "dramatic inflection."
• Strategic Focus: Reiteration of three core pillars: executing commercially, investing with discipline, and delivering patient value.

Miscellaneous:

• Pediatric Program: No updates provided on the pediatric program status during this call.
• Off-Label Usage: Acknowledges off-label utilization for CIC exists but confirms the company will pursue official label expansion via the Phase 3 trial to eliminate prescribing friction.
• DTC Strategy: Timing of the ad campaign was accelerated due to positive testing results; strategy is to monitor if increased website traffic translates to new patient starts.